Urea removal by hemofiltration and hemodiafiltration

Area of Science:

• Pediatric Nephrology
• Critical Care Medicine
• Renal Replacement Therapy

Background:

• Continuous hemofiltration (CAVH) is a standard treatment for fluid overload in neonates with acute renal failure.
• The potential for improved urea removal using continuous hemodiafiltration (CAVHD) in this population has not been fully explored.

Purpose of the Study:

• To compare the efficacy of CAVHD versus CAVH in enhancing urea removal in a preclinical model.
• To evaluate the feasibility of using neonatal-designed hemofilters for these procedures.

Main Methods:

• Continuous arteriovenous hemofiltration (CAVH) and continuous arteriovenous hemodiafiltration (CAVHD) were performed consecutively in anesthetized adult rabbits.
• Rabbits received urea infusions, and physiological parameters, plasma flow, and ultrafiltrate rates were monitored.
• A neonatal-designed polysulfone hemofilter (800-cm2) was utilized.

Main Results:

• Physiological and operational parameters were comparable between CAVH and CAVHD groups.
• CAVHD demonstrated a significant increase in urea clearance (4.74 ml/min) compared to CAVH (1.23 ml/min).
• No significant differences were observed in blood pressure, oncotic pressure, hematocrit, protein levels, or urea plasma levels between the two methods.

Conclusions:

• Continuous hemodiafiltration (CAVHD) offers superior urea removal compared to continuous hemofiltration (CAVH).
• The findings suggest that CAVHD may be a more effective treatment for managing uremia in neonates with acute renal failure.
• Further clinical assessment of CAVHD in neonatal populations is recommended.